Keraceuticals Is Pioneering A Breakthrough Drug Class Through Previously Unexploited Cancer Mechanisms
Keraceuticals is revolutionizing cancer therapy with its breakthrough drug, CIDD99, which targets a previously untapped mechanism. By disrupting calcium signaling pathways, CIDD99 depletes cancer cells’ critical calcium stores in the endoplasmic reticulum, halting their energy supply and triggering apoptosis. This innovative approach selectively eradicates cancer cells while sparing healthy tissues, offering a safer, more effective alternative to traditional therapies.
With a unique mechanism of action and promising pre-clinical results across multiple cancer types, Keraceuticals is transforming the landscape of oncology treatment.
Keraceuticals is led by a multidisciplinary team of experts with extensive experience in cancer research, drug development, and business strategy.
0
Dr. Cara Gonzales, DDS, PhD
Dr. Cara B. Gonzales is a trailblazing scientist and tenured professor at the University of Texas Health Science Center. Renowned for her groundbreaking research in oral cancer, she is the founder of Keraceuticals and the visionary behind CIDD99 and TRPC1, revolutionizing cancer therapy with innovative drug development. Dr. Gonzales holds five patents and has authored numerous publications, showcasing her expertise in oral cancer biology, tumorigenesis, and anti-cancer drug mechanisms. With a dedication to translational research and a proven track record of interdisciplinary collaboration, Dr. Gonzales is at the forefront of advancing targeted cancer treatments and improving patient outcomes.
0
Dr. Stan McHardy, PhD
Dr. Stanton McHardy is an accomplished Associate Professor of Chemistry and the Director of the Center for Innovative Drug Discovery at the University of Texas at San Antonio. With over 25 years of expertise in pharmaceutical R&D, his work spans neuroscience, cancer, and infectious disease drug discovery, leading to multiple investigational new drug applications. Dr. McHardy has pioneered advancements in small molecule drug development, earning numerous patents and publications. His collaborative with Dr. Cara Gonzales have resulted in innovative treatments for oral cancer, including the development of CIDD99. A recipient of honors such as the UTSA Innovator of the Year Award,
0
Dr. Anjuan Ramesh PhD, MBA
Dr. Anujan Ramesh is a biomedical engineer and translational drug delivery scientist with expertise in biologics delivery, immuno-oncology, cellular engineering, and regenerative medicine. He is an Assistant Professor of Pharmaceutical Sciences at the University of the Pacific and completed postdoctoral training in Bioengineering at Harvard University. His work spans high-concentration antibody formulation, sustained biologic delivery, immune-cell modulation, targeted electroporation, and nanoparticle-based immunotherapy. He has also co-founded and advised biotechnology ventures, bringing experience in scientific strategy, preclinical development, product positioning, and early-stage translational execution. His advisory perspective is grounded in translational drug delivery, immuno-oncology, and early-stage therapeutic development, with a focus on building scientifically rigorous, clinically relevant, and fundable biotechnology platforms.
0
Kimberly Sharp
Kimberly Sharp brings over 20 years of business expertise to Keraceuticals, with a proven track record of launching and scaling startups. Her deep experience in FDA regulatory pathways, global market strategy, and go-to-market execution positions her as a dynamic leader for this critical stage. Having secured regulatory approvals in over 60 countries and driven multiple successful capital raises, Kimberly excels at navigating complex challenges and delivering results. She combines entrepreneurial vision with strategic acumen, making her uniquely equipped to novel approach to previously unexploited cancer pathways. lead Keraceuticals in advancing groundbreaking biotechnology solutions.Series 7, 63
Email: cara@keraceuticals.net